Latest Insider Transactions at Cvs Health Corp (CVS)
This section provides a real-time view of insider transactions for Cvs Health Corp (CVS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CVS HEALTH Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CVS HEALTH Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 31
2023
|
Tilak Mandadi EVP, Chief Experience & Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
13,053
-39.22%
|
$848,445
$65.17 P/Share
|
|
Aug 31
2023
|
Prem S Shah EVP and Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,508
-6.44%
|
$228,020
$65.17 P/Share
|
|
Aug 03
2023
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Open market or private sale
|
Direct |
25,759
-45.88%
|
$1,906,166
$74.87 P/Share
|
|
May 18
2023
|
Fernando Aguirre Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,329
+4.22%
|
$91,701
$69.31 P/Share
|
|
May 18
2023
|
Jeffrey R. Balser Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,329
+28.86%
|
$91,701
$69.31 P/Share
|
|
May 18
2023
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,437
+4.95%
|
$99,153
$69.31 P/Share
|
|
May 18
2023
|
Anne A. Finucane Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,437
+14.1%
|
$99,153
$69.31 P/Share
|
|
May 18
2023
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,437
+50.0%
|
$99,153
$69.31 P/Share
|
|
May 03
2023
|
Karen S Lynch President and CEO |
BUY
Open market or private purchase
|
Direct |
14,000
+3.14%
|
$966,000
$69.75 P/Share
|
|
Apr 01
2023
|
Michelle A Peluso EVP and Co-President of Retail |
SELL
Payment of exercise price or tax liability
|
Direct |
98,299
-44.14%
|
$7,274,126
$74.31 P/Share
|
|
Apr 01
2023
|
Prem S Shah EVP and Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,221
-6.13%
|
$238,354
$74.31 P/Share
|
|
Apr 01
2023
|
Karen S Lynch President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
93,677
-45.34%
|
$6,932,098
$74.31 P/Share
|
|
Apr 01
2023
|
Sreekanth K Chaguturu EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,854
-22.39%
|
$137,196
$74.31 P/Share
|
|
Apr 01
2023
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,186
+19.4%
|
$161,764
$74.31 P/Share
|
|
Apr 01
2023
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,471
-4.61%
|
$108,854
$74.31 P/Share
|
|
Apr 01
2023
|
Daniel P Finke EVP/Pres, Health Care Benefits |
SELL
Payment of exercise price or tax liability
|
Direct |
3,856
-9.91%
|
$285,344
$74.31 P/Share
|
|
Feb 28
2023
|
Samrat S. Khichi EVP, CPO and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
47,881
+50.0%
|
$3,974,123
$83.54 P/Share
|
|
Feb 28
2023
|
J. David Joyner President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
23,940
+50.0%
|
$1,987,020
$83.54 P/Share
|
|
Feb 28
2023
|
Sreekanth K Chaguturu EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
120
-2.84%
|
$9,960
$83.54 P/Share
|
|
Feb 28
2023
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
179
-0.68%
|
$14,857
$83.54 P/Share
|
|
Feb 27
2023
|
Michelle A Peluso EVP and Co-President of Retail |
SELL
Payment of exercise price or tax liability
|
Direct |
12,304
-5.24%
|
$1,045,840
$85.77 P/Share
|
|
Feb 27
2023
|
Prem S Shah EVP and Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
226
-0.51%
|
$19,210
$85.77 P/Share
|
|
Feb 27
2023
|
Laurie P. Havanec EVP and Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,046
-16.56%
|
$343,910
$85.77 P/Share
|
|
Feb 27
2023
|
Sreekanth K Chaguturu EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
318
-7.59%
|
$27,030
$85.77 P/Share
|
|
Feb 02
2023
|
Karen S Lynch President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
206,610
+50.0%
|
-
|
|
Feb 02
2023
|
Michelle A Peluso EVP and Co-President of Retail |
BUY
Grant, award, or other acquisition
|
Direct |
192,554
+48.14%
|
-
|
|
Dec 31
2022
|
Thomas M Moriarty EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
292,856
-48.16%
|
$27,235,608
$93.19 P/Share
|
|
Dec 15
2022
|
Thomas M Moriarty EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
137,466
-9.95%
|
$13,471,668
$98.32 P/Share
|
|
Dec 15
2022
|
Thomas M Moriarty EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
137,466
+8.91%
|
$9,622,620
$70.13 P/Share
|
|
Dec 01
2022
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
153
-0.58%
|
$15,453
$101.65 P/Share
|
|
Nov 29
2022
|
Sreekanth K Chaguturu EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
442
-13.24%
|
$44,200
$100.88 P/Share
|
|
Nov 18
2022
|
Anne A. Finucane Director |
SELL
Bona fide gift
|
Indirect |
800
-2.69%
|
$77,600
$97.35 P/Share
|
|
Nov 17
2022
|
Edward J Ludwig Director |
BUY
Grant, award, or other acquisition
|
Direct |
131
+0.7%
|
$12,314
$94.93 P/Share
|
|
Nov 17
2022
|
Fernando Aguirre Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,323
+4.38%
|
$124,362
$94.93 P/Share
|
|
Nov 17
2022
|
Jeffrey R. Balser Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,323
+40.46%
|
$124,362
$94.93 P/Share
|
|
Nov 17
2022
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,402
+5.09%
|
$131,788
$94.93 P/Share
|
|
Nov 17
2022
|
Anne A. Finucane Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,428
+16.32%
|
$134,232
$94.93 P/Share
|
|
Nov 17
2022
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,402
+33.28%
|
$131,788
$94.93 P/Share
|
|
Sep 12
2022
|
Jeffrey R. Balser Director |
BUY
Grant, award, or other acquisition
|
Direct |
406
+39.42%
|
-
|
|
Aug 31
2022
|
Sreekanth K Chaguturu EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,735
+50.0%
|
-
|
|
Aug 31
2022
|
Tilak Mandadi EVP, Chief Experience & Tech |
BUY
Grant, award, or other acquisition
|
Direct |
99,847
+50.0%
|
-
|
|
Aug 31
2022
|
Prem S Shah EVP and Group President |
BUY
Grant, award, or other acquisition
|
Direct |
20,376
+50.0%
|
-
|
|
Aug 04
2022
|
Alan Lotvin EVP&President-PharmacyServices |
SELL
Open market or private sale
|
Direct |
22,541
-17.11%
|
$2,344,264
$104.0 P/Share
|
|
Aug 04
2022
|
Alan Lotvin EVP&President-PharmacyServices |
BUY
Exercise of conversion of derivative security
|
Direct |
22,541
+14.61%
|
$1,397,542
$62.21 P/Share
|
|
Aug 03
2022
|
Daniel P Finke EVP/Pres, Health Care Benefits |
SELL
Open market or private sale
|
Direct |
9,546
-22.89%
|
$954,600
$100.0 P/Share
|
|
Aug 03
2022
|
Daniel P Finke EVP/Pres, Health Care Benefits |
BUY
Exercise of conversion of derivative security
|
Direct |
9,546
+18.63%
|
$496,392
$52.37 P/Share
|
|
Aug 03
2022
|
Alan Lotvin EVP&President-PharmacyServices |
SELL
Open market or private sale
|
Direct |
120,899
-35.41%
|
$11,848,102
$98.0 P/Share
|
|
Aug 03
2022
|
Alan Lotvin EVP&President-PharmacyServices |
BUY
Exercise of conversion of derivative security
|
Direct |
120,899
+26.09%
|
$6,770,344
$56.26 P/Share
|
|
Jun 28
2022
|
Thomas M Moriarty EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
138,654
-6.87%
|
$13,172,130
$95.0 P/Share
|
|
Jun 28
2022
|
Thomas M Moriarty EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
138,654
+6.42%
|
$8,596,548
$62.28 P/Share
|